Last reviewed · How we verify
G-0081
At a glance
| Generic name | G-0081 |
|---|---|
| Sponsor | Dong-A Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Pharmacokinetic Comparison of Exforge® and G-0081 in Healthy Male Volunteers (PHASE1)
- A Randomized, Open Label, Single Dose, 2-Way Cross-over Clinical Trial to Compare the Safety and Pharmacokinetic Characteristics of Exforge® and G-0081 in Healthy Male Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- G-0081 CI brief — competitive landscape report
- G-0081 updates RSS · CI watch RSS
- Dong-A Pharmaceutical Co., Ltd. portfolio CI